Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05661643
Other study ID # AMC2203
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 28, 2023
Est. completion date December 31, 2027

Study information

Verified date March 2024
Source Asan Medical Center
Contact Min-Hee Ryu, MD, PhD
Phone 82-2-3010-5936
Email miniryu@amc.seoul.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to investigate the efficacy and safety of temozolomide in SDH deficiency GIST patients.


Description:

Wild type GISTs are less responsive to imatinib with a response rate of 23.1-44.6% and a median progressiion-free survival of 12.3-12.8 months. The efficacy of imatinib is limited in particular in SDH deficienctGIST with a reported response of 2%. Therefore, the development of a new therapeutic agents is urgently needed. Recently, a study of TKI-resistant SDH-deficient preclinical model showed that temozolomide, an alkylating agent, promotes DNA damage in tumor cells, leading to tumor cell killing. In a retrospective analysis, 2 out of 5 SDH deficient GIST patients treated with temozolomide showed partial response, suggesting its efficacy in this patient population. Based on these findings,The goal of this clinical trial is to investigate the efficacy and safety of temozolomide in SDH deficiency GIST patients. In addition, for exploratory purposes, aim to investigate the efficacy and safety of temozolomide in KIT and PDGFRA wild-type GIST without SDH deficiency.


Recruitment information / eligibility

Status Recruiting
Enrollment 29
Est. completion date December 31, 2027
Est. primary completion date December 1, 2026
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. Age 20 years or older, at the time of acquisition of informed consent 2. Histologically confirmed GIST with CD117(+), DOG-1(+) 3. Wild type GIST without KIT or PDGFRa gene mutations determined by Sanger sequencing and panel sequencing 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 ~ 2 5. Resolution of all adverse events with prior treatments to grade 0 or 1 by NCI-CTCAE version 5.0 6. At least one measurable lesion by RECIST version 1.1. 7. Adequate bone marrow, hepatic, renal, and other organ functions, before adjuvant imatinib treatment - Neutrophil >1,500/mm3 - Platelet > 100,000/mm3 - Hemoglobin >8.0 g/dL - Total bilirubin < 1.5 x upper limit of normal (ULN) - AST/ALT < 2.5 x ULN - Creatinine <1.5 x ULN 8. Life expectancy =12 weeks 9. Disease progression or discontinuation of treatment due to intolerable toxicity at least with palliative 1st line imatinib . 10. Washout period of previous TKIs or chemotherapy for more than 4 times the half life ((Imitinib and regorafenib need 1 week and sunitinib need 2 weeks.) 11. Provision of a signed written informed consent Exclusion Criteria: 1. Confirmed GIST with KIT or PDGFRa gene mutations determined by Sanger sequencing and panel sequencing 2. Women of child-bearing potential who are pregnant or breast feeding 3. Women or men who are not willing to use effective contraception entering the study period or until at least 6 months after the last study drug administration 4. If any of the following applies within = 6 months prior to starting study enrollment : Myocardial Infarction, severe instable angina, coronary/peripheral bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, treatment required severe arrhythmia 5. Uncontrolled infection 6. Acute and chronic liver disease and all chronic liver impairment.(But Patients with stable chronic hepatitis B are eligible 7. Acute, or chronic medical or psychiatric condition or laboratory abnormality such as active uncontrolled infection that difficult to study participation in the judgment of the investigator 8. Known diagnosis of HIV infection (HIV testing is not mandatory). 9. History of another primary malignancy that is currently clinically significant or currently requires active intervention. 10. Alcohol or substance abuse disorder 11. The patients with NTRK fusion 5)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Temozolomide capsule
Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)

Locations

Country Name City State
Korea, Republic of Asan Medical Center, University of Ulsan College of Medicine Seoul

Sponsors (1)

Lead Sponsor Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective respone rate in SDH deficiency wild type GIST complet response+partial response defined by RECIST v1.1 up to 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT05385549 - 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk Phase 2
Recruiting NCT05905887 - Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor Phase 2
Completed NCT01933958 - Regorafenib Post-marketing Surveillance in Japan
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT01440959 - Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 Phase 2
Completed NCT00718562 - Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib Phase 2
Completed NCT00385203 - The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). Phase 2
Completed NCT00137449 - Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor Phase 2
Completed NCT00237172 - Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) Phase 2
Terminated NCT04409223 - Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib Phase 3
Active, not recruiting NCT03556384 - Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Phase 2
Recruiting NCT04106024 - Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial Phase 2
Completed NCT02171286 - The Oncopanel Pilot (TOP) Study N/A
Completed NCT01114087 - Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility N/A
Recruiting NCT05366816 - ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST Phase 2
Recruiting NCT03602092 - Observational Registry Data on GIST Patients
Recruiting NCT05197933 - Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach N/A
Completed NCT02931929 - MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT Phase 1/Phase 2
Withdrawn NCT05080621 - Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) Phase 1/Phase 2
Completed NCT02571036 - A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Phase 1